Drug-Drug Interaction Between Methotrexate and Levetiracetam Resulting in Delayed Methotrexate Elimination by Bain, Emily et al.
Butler University
Digital Commons @ Butler University
Scholarship and Professional Work – COPHS College of Pharmacy & Health Sciences
2014
Drug-Drug Interaction Between Methotrexate and
Levetiracetam Resulting in Delayed Methotrexate
Elimination
Emily Bain
Ruemu E. Birhiray
David J. Reeves
Butler University, dreeves@butler.edu
Follow this and additional works at: http://digitalcommons.butler.edu/cophs_papers
Part of the Pharmaceutical Preparations Commons, and the Pharmacy and Pharmaceutical
Sciences Commons
This Article is brought to you for free and open access by the College of Pharmacy & Health Sciences at Digital Commons @ Butler University. It has
been accepted for inclusion in Scholarship and Professional Work – COPHS by an authorized administrator of Digital Commons @ Butler University.
For more information, please contact fgaede@butler.edu.
Recommended Citation
Bain, Emily; Birhiray, Ruemu E.; and Reeves, David J., "Drug-Drug Interaction Between Methotrexate and Levetiracetam Resulting in
Delayed Methotrexate Elimination" (2014). Scholarship and Professional Work – COPHS. Paper 214.
http://digitalcommons.butler.edu/cophs_papers/214
Drug-Drug Interaction Between Methotrexate and Levetiracetam 
Resulting in Delayed Methotrexate Elimination 
Emily Bain, PharmD1 
Ruemu E. Birhiray, MD2 
David J. Reeves, PharmD, BCOP1,3 
1St Vincent Hospital, Indianapolis, IN, USA 
2Hematology Oncology of Indiana, Indianapolis, IN, USA 
3Butler University, Indianapolis, IN, USA 
 
 
Abstract 
 
Objective: To report a case of delayed methotrexate (MTX) elimination while receiving concomitant 
levetiracetam. Case Report: A 46-year-old man with relapsed osteosarcoma of the base of the skull 
receiving high-dose MTX tolerated his first cycle of MTX with elimination to nontoxic MTX levels (≤0.1 
µmol/L) within 90 hours. After hospital discharge, the patient experienced seizures secondary to brain 
metastasis and started on levetiracetam, which was continued as maintenance therapy. The patient 
experienced delayed MTX elimination during cycles 2, 3, and 4 while receiving levetiracetam. On 
average, elimination to nontoxic MTX levels took 130 hours (106-144 hours). Before the fifth cycle of 
MTX, lorazepam was substituted for the levetiracetam. MTX was eliminated to nontoxic levels within 95 
hours. During all cycles, the patient received standard supportive care and serum creatinine remained 
stable. No other drugs known to interact with MTX were administered. Discussion: This possible drug 
interaction has only been reported once in the pediatric population. With a score of 6 on the Drug 
Interaction Probability Scale for evaluating causation of drug interactions, it is probable that the delayed 
MTX elimination was caused by an interaction with levetiracetam. Conclusion: Coadministration of 
levetiracetam and MTX may result in delayed elimination of MTX, increasing the likelihood of toxicity. 
Consideration should be given to temporarily switching from levetiracetam to another antiepileptic (ie, 
lorazepam) to prevent this interaction. This is particularly important in those experiencing delayed 
elimination with prior cycles of concomitant MTX and levetiracetam or those at greater risk for MTX 
toxicity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Patients with cancer are at a high risk for drug-drug interactions because of the complex nature of 
their treatment regimens. In fact, it has been reported that 12% to 63% of patients with cancer are 
potentially exposed to interacting medications, and 75% of these interactions may be classified as 
moderate or severe.1 Chemotherapeutic agents have complex pharmacological profiles, narrow 
therapeutic indexes, and steep dose-toxicity curves.2 These drug properties leave little to no room 
for alterations in the elimination or distribution of chemotherapeutic agents. Further complicating 
the use of potentially toxic chemotherapy regimens is the complex nature of the oncology patient. 
Many are on multiple maintenance medications to treat chronic conditions in addition to those 
necessary to control the symptoms of their malignancy. Patients who develop central nervous 
system metastases may experience seizure episodes and require long-term therapy with an 
antiepileptic agent; however, optimal therapy with ongoing oncological treatment has not been 
established.3 When choosing an antiepileptic medication, agents with a low potential for 
interacting with chemotherapy and favorable safety profiles, such as levetiracetam, are preferred.3 
Here, we present a case of delayed elimination when high-dose methotrexate (MTX) was 
administered concomitantly with levetiracetam. 
 
Case Report 
 
A 46-year-old Caucasian male with relapsed osteosarcoma presented for chemotherapy with high-
dose MTX alternating with ifosfamide and etoposide according to the regimen utilized in the SFOP 
OS94 protocol.4 He had a past medical history of retinoblastoma that was treated with radiation at 
the age of 11 months, diabetes mellitus, hypertension, and hyperlipidemia. Home medications 
included lisinopril, simvastatin, glipizide, and aspirin. He originally presented with headaches and 
significant sinus complaints and was found to have radiation-induced osteosarcoma of the base of 
the skull. This was treated with cisplatin and doxorubicin for 6 cycles followed by surgical 
resection and adjuvant concurrent chemoradiation with carboplatin. The patient was disease free 
for approximately 1 year, when he presented with epistaxis. On magnetic resonance imaging, he 
was found to have a mass within the ethmoidal cells and the right orbit. On biopsy, this was 
confirmed to be recurrent osteosarcoma.  
 
During cycle 1 of chemotherapy for recurrent disease, the patient was admitted to the oncology 
unit and received 24 g of MTX (12 g/m2) intravenously (IV) over 4 hours (height = 170 cm, weight 
= 80 kg). Supportive care included leucovorin rescue with 25 mg orally every 6 hours and urinary 
alkalinization with 100 mEq of sodium bicarbonate per liter of dextrose 5% in water at 125 mL/h 
(3 L/d). Urine pH remained above 7, and recorded input and output were well balanced throughout 
the hospital stay. Prior imaging in addition to history and physical exam on admission did not 
reveal the presence of any findings suggestive of ascites or pleural effusion. Serum MTX levels 
were drawn 24, 48, and 72 hours after the start of the MTX infusion, and every morning thereafter 
until the level was <0.1 µmol/L. Baseline serum creatinine was 0.9 mg/dL, and aspartate and 
alanine aminotransferases (AST/ALT) were within normal limits (10 and 39 U/L, respectively). 
Additional medications administered to the patient during the admission were lisinopril, 
simvastatin, insulin glargine, insulin aspart, oxycodone, prochlorperazine, ondansetron, and 
famotidine. Aspirin was held until hospital discharge. The patient tolerated the first cycle of MTX 
well and eliminated it to nontoxic levels (≤0.1 µmol/L) within 90 hours (Table 1). After hospital 
discharge, the patient developed seizures as a result of large right-parietal/occipital lobe lesions 
associated with edema and shifting toward the left hemisphere. Levetiracetam was initiated and 
continued as maintenance therapy at 1 g orally every 12 hours, and 7 days after starting 
levetiracetam, chemotherapy treatments were resumed.  
 
 
 
During cycles 2, 3, and 4 of MTX, the patient experienced delayed elimination, with an average 
time to nontoxic levels of 130 hours (106-155 hours; Figure 1). The patient continued to receive 
the same dose of MTX as cycle 1 (12 g/m2) along with the same supportive care. Urine pH 
remained above 7.0 from the start of each MTX infusion until levels were nontoxic, and recorded 
input and output remained well balanced. History and physical exams during each admission did 
not reveal the presence of any findings suggestive of ascites or pleural effusion. Changes to the 
patient’s medications throughout cycles 2 to 4 included the addition of fluoxetine prior to cycle 3 
and the discontinuation of lisinopril during cycle 4. No medications known to interact with MTX 
were administered during the hospital stays for cycles 2 to 5 of MTX administration. During each 
of these cycles, leucovorin was increased to 50-mg IV every 6 hours because of the elevated MTX 
levels at 24 hours and continued until levels were nontoxic. 
 
Prior to the fifth cycle of MTX, lorazepam was substituted for levetiracetam to control the patient’s 
seizures. MTX was administered the same as in cycles 1 to 4 with the same supportive care. Urine 
pH remained above 7, and recorded input and output were well balanced. Leucovorin was 
increased to 50-mg IV every 6 hours because of the elevated MTX levels at 24 hours. Overall, the 
patient eliminated MTX to nontoxic levels within 95 hours. 
 
 
 
 
 
 
 
 
 
Discussion 
It is well known that MTX interacts with multiple medications. Drugs that are highly protein 
bound, including many antiepileptics, have been shown to reduce renal clearance of MTX through 
protein-drug displacement and lead to increased serum concentrations, placing patients at risk for 
toxicity.2 Additionally, active renal tubular secretion of MTX has been shown to be reduced by 
drugs such as probenecid and weak organic acids.5 Delayed MTX elimination can lead to 
significant toxicities, such as acute renal failure, bone marrow suppression, mucositis, and 
hepatotoxicity. Levetiracetam displays less protein binding than other antiepileptics (<5%).6 
Additionally, levetiracetam lacks any significant effects on the metabolism of medications via 
hepatic enzymes (cytochrome P450, glucuronidation, etc) and is often a preferred agent because 
of the decreased likelihood of adverse interactions and subsequent toxicities.7 
A possible mechanism responsible for decreased MTX elimination when coadministered with 
levetiracetam has not been proposed; however, it may be because of competition for tubular 
secretion. Though levetiracetam undergoes glomerular filtration, the metabolite ucb L057 is 
eliminated via active tubular secretion.8 When levetiracetam was coadministered with probenecid, 
renal clearance of the metabolite ucb L057 was decreased by 60% and the Cmax doubled.8 MTX 
also undergoes active tubular secretion and interacts with many medications that compete for 
secretion. When administered with probenecid, MTX levels doubled.9 Given the similar 
interactions with probenecid, it is plausible that with the common route of elimination, MTX and 
levetiracetam’s metabolite ucb L057 may compete with each other for tubular secretion. 
A search of the literature was performed using the search term methotrexate and levetiracetam 
revealing 1 publication relating to a possible drug interaction. A pediatric case report was recently 
published in which a 15-year-old boy with B-cell lymphoblastic leukemia was receiving treatment 
with high-dose MTX.10 During treatment, he developed seizures, was diagnosed with brain 
metastases, and initiated on oral levetiracetam. After the third infusion of high-dose MTX (5 
g/m2/24 hour) the patient developed vomiting, renal failure, and hypertension. He was also found 
to have an elevated serum creatinine and MTX level and required treatment with carboxypeptidase 
G2. It was noted that the patient had no prior risk factors for MTX toxicity and was receiving no 
concomitant interacting medications. 
In the present case report, the patient did not experience any toxicity; however, MTX levels were 
above the goal ranges at 24 (goal MTX level <10 µmol/L), 48 (goal MTX level <1 µmol/L), and 
72 (goal MTX level <0.1 µmol/L) hours after the start of the MTX infusion when receiving 
concomitant levetiracetam (Table 1). During cycle 5, the 24-hour MTX level was above goal 
range; however, this may be because of the effect of residual levetiracetam present from 
administration prior to hospital admission. Given a half-life of approximately 8 hours, it is 
plausible that levetiracetam was still being eliminated and available to interact with MTX. This 
was not the case for the 48-hour level, which was 0.69 µmol/L, well below the goal of 1 µmol/L. 
Most important, the time to nontoxic MTX levels was shorter when levetiracetam was not 
coadministered with the high-dose MTX (Table 1). During the fourth cycle of MTX, elimination 
was not as delayed as during cycles 2 and 3. During all 3 of these cycles, the patient received the 
same care, including the coadministration of levetiracetam; however, during cycle 4, the patient’s 
lisinopril was held during the hospital stay. Though no interaction has been reported between 
lisinopril and MTX, the renal vasoconstriction caused by this medication in the efferent arteriole 
may decrease blood flow through the glomerulus, which theoretically could decrease MTX 
elimination. Holding lisinopril may have slightly improved MTX clearance during cycle 4. 
Lisinopril was administered during cycles 1 to 3 and during cycle 5. 
Unfortunately, little data exist regarding the optimal treatment of seizures in cancer patients with 
brain metastases. There are a multitude of drug interactions associated with many antiepileptic 
medications, particularly via their hepatic enzyme–inducing effects and protein-binding effects. 
For these reasons, agents such as phenytoin, phenobarbital, carbamazepine, oxcarbazepine, and 
topiramate are not recommended as first-line agents.11 Valproate has been associated with 
increased hematological toxicity when combined with chemotherapy and is best avoided if 
possible.12 Benzodiazepines may be recommended in the acute treatment of seizures because of 
their relative lack of drug interactions. For long-term treatment of seizures associated with brain 
metastases, it has been recommended to utilize agents relatively free of drug interactions 
(levetiracetam, gabapentin, lamotrigine, topiramate, and pregabalin).11 
Until now, a potential drug interaction between MTX and levetiracetam has not been reported in 
adults. The Drug Interaction Probability Scale (DIPS) was used to evaluate the causation of a 
potential drug interaction between MTX and levetiracetam.13 With a DIPS score of 6, it is probable 
that the delayed MTX elimination seen in this patient was the result of an interaction with 
levetiracetam as evidenced by more rapid MTX elimination during cycles 1 and 5 with no 
concomitant levetiracetam and delayed elimination during cycles 2, 3, and 4 with concomitant 
levetiracetam (Table 2). Therefore, an interaction between MTX and levetiracetam cannot be ruled 
out. Patients receiving concomitant levetiracetam and MTX who are experiencing delayed 
elimination may benefit from the substitution of levetiracetam until MTX levels are nontoxic. 
When possible, consideration should be given to temporarily switching from levetiracetam to 
another antiepileptic (ie, lorazepam) to prevent this interaction. This is particularly important in 
those who experienced delayed elimination with prior cycles of concomitant MTX and 
levetiracetam coadministration or those felt to be at greater risk for MTX toxicity. 
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